BrainStorm Cell up after FDA considers Citizen Petition for ALS therapy review

Brainstorm Cell Therapeutics

08/07/2025 14:22

** Shares of drug developer BrainStorm Cell Therapeutics BCLI.O up 6.1% at $1.21 premarket

** Co says FDA has considered a citizen petition requesting a new review of the data supporting co's therapy NurOwn for amyotrophic lateral sclerosis

** A citizen petition to the FDA is a regulatory process, in which anyone can request the agency to act on specific issues like reviewing data, issuing new guidance, or enforcing actions

** Co says the review "will provide a critical opportunity to reaffirm its potential as therapy for amyotrophic lateral sclerosis"

** ALS is a rare and fatal neurodegenerative disease, which affects voluntary control of arms and legs, and leads to breathing trouble

** BCLI says it supports exploration of potential regulatory pathways that may allow appropriate access to NurOwn for patients with ALS

** Up to last close, stock down 49.8% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))